Navigation Links
BD Announces Results For 2011 Third Fiscal Quarter
Date:8/2/2011

FRANKLIN LAKES, N.J., Aug. 2, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.014 billion for the third fiscal quarter ended June 30, 2011, representing an increase of 10.0 percent from the prior-year period.  On a foreign currency-neutral basis, revenues increased 4.8 percent.

“We are pleased with our solid results this quarter, with all three segments contributing to growth,” said Edward J. Ludwig, Chairman and Chief Executive Officer.  “Gross margin expansion reflecting favorable product mix has offset some of the headwinds we have been facing as a result of a challenging macroeconomic environment and increased raw material costs.”

Agreement to Acquire Carmel Pharma, ABOn July 27, 2011, the Company announced that it had signed a definitive agreement to acquire Carmel Pharma, AB, a Swedish company that manufactures the PhaSeal® System. This is the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials.  The acquisition is expected to close prior to the end of this fiscal year.

Third Quarter and Nine-Month Fiscal 2011 Operating ResultsReported diluted earnings per share from continuing operations for the third quarter were $1.51, compared with $1.23 in the prior-year period, representing a 22.8 percent increase, or 13.8 percent on a currency-neutral basis.

For the nine-month period ending June 30, 2011, reported diluted earnings per share from continuing operations were $4.23, compared with $3.66 in the prior-year period. The prior-year period included a non-cash charge of $8.9 million, or $0.04 per share, related to healthcare reform impacting Medicare Part D reimbursements. Excluding that item, earnings per share from continuing operations increased by 14.3 percent, compared with adjusted diluted earnings per share from continuing operations of $3.70 in the prior-year period, or 8.1 percent on a currency-neutral basis.

Segment ResultsIn the BD Medical segment, worldwide revenues for the quarter were $1.045 billion, representing an increase of 10.5 percent compared with the prior-year period, or 4.9 percent on a foreign currency-neutral basis. Revenues reflected strong sales of Pharmaceutical Systems products and international safety, along with solid sales of Diabetes Care products.  For the nine-month period ended June 30, 2011, BD Medical revenues increased 4.0 percent, or 1.7 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $631 million, representing an increase of 9.6 percent compared with the prior-year period, or 4.8 percent on a foreign currency-neutral basis. Revenues reflected solid growth in Preanalytical Systems safety-engineered products and strong growth in both the Women’s Health and Cancer and the Infectious Disease product offerings in the Diagnostics Systems unit. For the nine-month period ended June 30, 2011, BD Diagnostics revenues increased 6.4 percent, or 3.9 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $338 million, representing an increase of 9.3 percent compared with the prior-year period, or 4.3 percent on a foreign currency-neutral basis. Segment growth was driven primarily by instrument and reagent sales in the Cell Analysis unit. Discovery Labware revenues in the U.S. were negatively impacted by weakness in core consumables. The segment’s revenues also reflected softness in Western Europe due to government research funding delays.  For the nine-month period ended June 30, 2011, BD Biosciences revenues increased by 5.7 percent, or 2.7 percent on a foreign currency-neutral basis.

Geographic ResultsThird quarter revenues in the U.S. were $855 million, representing an increase of 5.7 percent compared with the prior-year period.  Revenues outside of the U.S. were $1.159 billion, representing an increase of 13.4 percent compared with the prior-year period, or 4.1 percent on a foreign currency-neutral basis. Revenues reflected continued strength in emerging markets, which was partially offset by ongoing challenging macroeconomic conditions in Western Europe.  For the nine-month period ended June 30, 2011, revenues in the U.S. were $2.513 billion, representing an increase of 2.4 percent compared with the prior-year period. Revenues outside of the U.S. were $3.265 billion, representing an increase of 7.2 percent compared with the prior-year period, or 2.8 percent on a foreign currency-neutral basis.

Fiscal Year 2011 OutlookReported revenue growth guidance for the full fiscal year 2011 is expected to be at the higher end of the previously communicated range of 5 to 6 percent compared with fiscal year 2010, due to the anticipated effects of favorable currency. On a foreign currency-neutral basis, the Company is lowering its revenue growth guidance to an increase of about 3 percent versus its previously communicated guidance of about 3.5 percent, mainly due to lower than expected sales in Western Europe.

The Company is raising its previous guidance for reported diluted earnings per share from continuing operations for fiscal year 2011 from $5.55-$5.65 to $5.65-$5.70, an increase of approximately 15 to 16 percent over fiscal year 2010, due to the anticipated effects of favorable currency. Diluted earnings per share from continuing operations for fiscal year 2011 are expected to increase 14 to 15 percent over adjusted diluted earnings per share from continuing operations of $4.94, excluding the specified item, for fiscal year 2010.  The specified item represents the aforementioned 2010 non-cash charge of $0.04 per share related to healthcare reform. On a currency-neutral basis, the Company continues to expect diluted earnings per share from continuing operations to increase about 10 percent over adjusted diluted earnings per share in the prior-year period, despite lower than expected revenue growth and higher resin costs.

Conference Call InformationA conference call regarding BD’s third quarter results and its expectations will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, August 2, 2011. The slides are available concurrent with the issuance of this press release at www.bd.com/investors. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 855-859-2056 (domestic) and 404-537-3406 (international) through the close of business on Tuesday, August 9, 2011, access code 82566570.

Non-GAAP Financial MeasuresThis news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled “Fiscal Year 2011 Outlook”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share.  Forward-looking statements may be identified by the use of words such as “expect”, “estimate” or words of similar meaning in conjunction with statements of future performance.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to:  the potential adverse effects that the earthquake and tsunami in Japan and the situation regarding the Fukushima, Japan nuclear power plant may have on BD’s future operations in Japan; the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for BD’s products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic situation on BD’s ability to access credit markets and finance its operations, the demand for BD’s products and services, or its suppliers’ ability to provide products needed for BD’s operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting BD’s business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; BD’s ability to successfully integrate any businesses it acquires; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission.  BD does not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations. BECTON DICKINSON AND COMPANYCONSOLIDATED INCOME STATEMENTS(Unaudited; Amounts in thousands, except per share data)Three Months Ended June 30,20112010% ChangeREVENUES

$

2,014,081

$

1,830,91110.0Cost of products sold951,980883,4347.8Selling and administrative 474,646416,46814.0Research and development115,748108,0477.1TOTAL OPERATING COSTSAND EXPENSES1,542,3741,407,9499.5OPERATING INCOME471,707422,96211.5Interest income11,5082,094NM Interest expense(22,211)(13,085)69.7Other (expense) income, net(363)1,402NM INCOME FROM CONTINUING OPERATIONS BEFOREINCOME TAXES460,641413,37311.4Income tax provision122,531119,2132.8INCOME FROM CONTINUING OPERATIONS338,110294,16014.9INCOME FROM DISCONTINUED OPERATIONS   NET OF INCOME TAX PROVISION OF$111 AND $4,340, RESPECTIVELY4,94812,748(61.2)NET INCOME

$

343,058

$

306,90811.8EARNINGS PER SHAREBasic:Income from continuing operations

$

1.54

$

1.2622.2Income from discontinued operations

$

0.02

$

0.05(60.0)Net income (1)

$

1.57

$

1.3218.9Diluted:Income from continuing operations

$

1.51

$

1.2322.8Income from discontinued operations

$

0.02

$

0.05(60.0)Net income (1)

$

1.53

$

1.2918.6AVERAGE SHARES OUTSTANDINGBasic218,966233,242Diluted223,567238,319NM - Not Meaningful(1) Total per share amounts may not add due to roundingBECTON DICKINSON AND COMPANYCONSOLIDATED INCOME STATEMENTS(Unaudited; Amounts in thousands, except per share data)Nine Months Ended June 30,20112010% ChangeREVENUES

$

5,778,109

$

5,499,1385.1Cost of products sold2,738,0002,642,2503.6Selling and administrative 1,364,5431,283,2176.3Research and development350,441307,39114.0TOTAL OPERATING COSTSAND EXPENSES4,452,9844,232,8585.2OPERATING INCOME1,325,1251,266,2804.6Interest income41,29420,535NM Interest expense(61,685)(38,985)58.2Other expense, net(7,481)(788)NM INCOME FROM CONTINUING OPERATIONS BEFOREINCOME TAXES1,297,2531,247,0424.0Income tax provision333,804363,755(8.2)INCOME FROM CONTINUING OPERATIONS963,449883,2879.1INCOME FROM DISCONTINUED OPERATIONS   NET OF INCOME TAX PROVISION OF$711 AND $13,058, RESPECTIVELY7,56637,628(79.9)NET INCOME

$

971,015

$

920,9155.4EARNINGS PER SHAREBasic:Income from continuing operations

$

4.33

$

3.7515.5Income from discontinued operations

$

0.03

$

0.16(81.3)Net income

$

4.36

$

3.9111.5Diluted:Income from continuing operations

$

4.23

$

3.6615.6Income from discontinued operations

$

0.03

$

0.16(81.3)Net income

$

4.26

$

3.8211.5AVERAGE SHARES OUTSTANDINGBasic222,674235,316Diluted227,782241,151NM - Not MeaningfulBECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY SEGMENT AND GEOGRAPHIC AREA(Unaudited; Amounts in thousands)Three Months Ended June 30,20112010% ChangeBD MEDICAL   United States

$

416,729

$

381,7619.2   International628,107563,76111.4TOTAL

$

1,044,836

$

945,52210.5BD DIAGNOSTICS   United States

$

312,802

$

303,5213.1   International318,557272,74816.8TOTAL

$

631,359

$

576,2699.6BD BIOSCIENCES   United States

$

125,933

$

124,1461.4   International211,953184,97414.6TOTAL

$

337,886

$

309,1209.3TOTAL REVENUES   United States

$

855,464

$

809,4285.7   International1,158,6171,021,48313.4TOTAL

$

2,014,081

$

1,830,91110.0BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY SEGMENT AND GEOGRAPHIC AREA(Unaudited; Amounts in thousands)Nine Months Ended June 30,20112010% ChangeBD MEDICAL   United States

$

1,220,744

$

1,196,1052.1   International1,731,9691,641,7225.5TOTAL

$

2,952,713

$

2,837,8274.0BD DIAGNOSTICS   United States

$

932,269

$

906,5662.8   International906,160820,84910.4TOTAL

$

1,838,429

$

1,727,4156.4BD BIOSCIENCES   United States

$

360,234

$

351,9332.4   International626,733581,9637.7TOTAL

$

986,967

$

933,8965.7TOTAL REVENUES   United States

$

2,513,247

$

2,454,6042.4   International3,264,8623,044,5347.2TOTAL

$

5,778,109

$

5,499,1385.1BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSThree Months Ended June 30,(Unaudited; Amounts in thousands)United States20112010 % Change BD MEDICAL   Medical Surgical Systems

$

244,756

$

239,8662.0   Diabetes Care100,46596,0714.6   Pharmaceutical Systems71,50845,82456.0TOTAL

$

416,729

$

381,7619.2BD DIAGNOSTICS   Preanalytical Systems

$

162,589

$

159,2282.1   Diagnostic Systems150,213144,2934.1TOTAL

$

312,802

$

303,5213.1BD BIOSCIENCES   Cell Analysis

$

89,162

$

84,3655.7   Discovery Labware36,77139,781(7.6)TOTAL

$

125,933

$

124,1461.4TOTAL UNITED STATES

$

855,464

$

809,4285.7BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSThree Months Ended June 30, (continued)(Unaudited; Amounts in thousands)International % Change 20112010 Reported FXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

284,262

$

253,68712.13.09.1   Diabetes Care119,719101,08118.47.810.6   Pharmaceutical Systems224,126208,9937.2(1.8)9.0TOTAL

$

628,107

$

563,76111.42.19.3BD DIAGNOSTICS   Preanalytical Systems

$

167,737

$

144,29816.26.010.2   Diagnostic Systems150,820128,45017.47.59.9TOTAL

$

318,557

$

272,74816.86.710.1BD BIOSCIENCES   Cell Analysis

$

165,866

$

146,06813.65.58.1   Discovery Labware46,08738,90618.58.99.6TOTAL

$

211,953

$

184,97414.66.28.4TOTAL INTERNATIONAL

$

1,158,617

$

1,021,48313.44.19.3BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSThree Months Ended June 30, (continued)(Unaudited; Amounts in thousands)Total % Change 20112010 Reported FXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

529,018

$

493,5537.22.54.7   Diabetes Care220,184197,15211.76.25.5   Pharmaceutical Systems295,634254,81716.08.67.4TOTAL

$

1,044,836

$

945,52210.54.95.6BD DIAGNOSTICS   Preanalytical Systems

$

330,326

$

303,5268.84.04.8   Diagnostic Systems301,033272,74310.45.74.7TOTAL

$

631,359

$

576,2699.64.84.8BD BIOSCIENCES   Cell Analysis

$

255,028

$

230,43310.75.65.1   Discovery Labware82,85878,6875.30.64.7TOTAL

$

337,886

$

309,1209.34.35.0TOTAL REVENUES

$

2,014,081

$

1,830,91110.04.85.2BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSNine Months Ended June 30,(Unaudited; Amounts in thousands)United States20112010 % Change BD MEDICAL   Medical Surgical Systems

$

733,582

$

751,032(2.3)   Diabetes Care295,989285,1503.8   Pharmaceutical Systems191,173159,92319.5TOTAL

$

1,220,744

$

1,196,1052.1BD DIAGNOSTICS   Preanalytical Systems

$

481,624

$

465,3953.5   Diagnostic Systems450,645441,1712.1TOTAL

$

932,269

$

906,5662.8BD BIOSCIENCES   Cell Analysis

$

252,423

$

240,1525.1   Discovery Labware107,811111,781(3.6)TOTAL

$

360,234

$

351,9332.4TOTAL UNITED STATES

$

2,513,247

$

2,454,6042.4BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSNine Months Ended June 30, (continued)(Unaudited; Amounts in thousands)International % Change 20112010 Reported FXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

812,752

$

756,9637.42.15.3   Diabetes Care345,837301,50814.79.65.1   Pharmaceutical Systems573,380583,251(1.7)(3.5)1.8TOTAL

$

1,731,969

$

1,641,7225.51.54.0BD DIAGNOSTICS   Preanalytical Systems

$

467,570

$

425,9679.84.65.2   Diagnostic Systems438,590394,88211.15.75.4TOTAL

$

906,160

$

820,84910.45.25.2BD BIOSCIENCES   Cell Analysis

$

498,864

$

464,0917.53.14.4   Discovery Labware127,869117,8728.52.36.2TOTAL

$

626,733

$

581,9637.72.94.8TOTAL INTERNATIONAL

$

3,264,862

$

3,044,5347.22.84.4BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSNine Months Ended June 30, (continued)(Unaudited; Amounts in thousands)Total % Change 20112010 Reported FXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

1,546,334

$

1,507,9952.5(0.1)2.6   Diabetes Care641,826586,6589.46.82.6   Pharmaceutical Systems764,553743,1742.91.51.4TOTAL

$

2,952,713

$

2,837,8274.01.72.3BD DIAGNOSTICS   Preanalytical Systems

$

949,194

$

891,3626.54.02.5   Diagnostic Systems889,235836,0536.43.82.6TOTAL

$

1,838,429

$

1,727,4156.43.92.5BD BIOSCIENCES   Cell Analysis

$

751,287

$

704,2436.73.82.9   Discovery Labware235,680229,6532.6(0.5)3.1TOTAL

$

986,967

$

933,8965.72.73.0TOTAL REVENUES

$

5,778,109

$

5,499,1385.12.62.5BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONSAFETY REVENUES(Unaudited; Amounts in thousands)Three Months Ended June 30, % Change 20112010 Reported FXNFX ImpactTOTAL SAFETY REVENUES   United States

$

280,696

$

270,6043.73.7-   International198,417157,85125.714.111.6TOTAL

$

479,113

$

428,45511.87.64.2BY SEGMENT   BD Medical

$

223,460

$

195,40014.410.44.0   BD Diagnostics255,653233,0559.75.24.5TOTAL

$

479,113

$

428,45511.87.64.2Nine Months Ended June 30, % Change 20112010 Reported FXNFX ImpactTOTAL SAFETY REVENUES   United States

$

828,002

$

825,4630.30.3-   International545,530461,51718.211.96.3TOTAL

$

1,373,532

$

1,286,9806.74.52.2BY SEGMENT   BD Medical

$

641,635

$

610,2625.13.02.1   BD Diagnostics731,897676,7188.25.82.4TOTAL

$

1,373,532

$

1,286,9806.74.52.2BECTON DICKINSON AND COMPANYSUPPLEMENTAL INFORMATIONFY2011 Year-to-Date Reconciliation(Unaudited; Amounts in millions, except per share data)Nine Months Ended June 30,ReportedReportedAdjustedAdjustedFY 2011FY 2010Tax (1)FY 2010% GrowthDiluted Earnings per Sharefrom Continuing Operations

$

4.23

$

3.66

$

0.04

$

3.7014.3%(1) Represents a non-cash charge related to healthcare reform
impacting Medicare Part D reimbursements.  
BECTON DICKINSON AND COMPANYSUPPLEMENTAL INFORMATIONQuarter-to-Date Fiscal 2011 Reconciliation - FX Impact(Unaudited; Amounts in millions, except per share data)Three Months Ended June 30,ReportedReportedReported Growth Foreign CurrencyFY10 HedgeTotalFXNFXN FY 2011FY 2010$TranslationLossFX Change GrowthREVENUES

$

2,014

$

1,831

$

183

$

94

$

1

$

96

$

884.8%Diluted Earnings per Sharefrom Continuing Operations

$

1.51

$

1.23

$

0.28

$

0.11

$

0.00

$

0.11

$

0.1713.8%FXN = Foreign Currency NeutralAll figures rounded. Totals may not add due to rounding.BECTON DICKINSON AND COMPANYSUPPLEMENTAL INFORMATIONYear-to-Date Fiscal 2011 Reconciliation - FX Impact(Unaudited; Amounts in millions, except per share data)Nine Months Ended June 30,ReportedAdjustedAdjusted Growth Foreign CurrencyFY10 HedgeTotalAdjusted FXNFXN FY 2011FY 2010$TranslationLossFX Change GrowthREVENUES

$

5,778

$

5,499

$

279

$

94

$

43

$

136

$

1432.6%Diluted Earnings per Sharefrom Continuing Operations

$

4.23

$

3.70

$

0.53

$

0.12

$

0.11

$

0.23

$

0.308.1%FXN = Foreign Currency NeutralAll figures rounded. Totals may not add due to rounding.BECTON DICKINSON AND COMPANYSUPPLEMENTAL INFORMATIONFY2010 Total Year ReconciliationReported Diluted Earnings per Share from Continuing Operations

$

4.90Tax (1)0.04Adjusted Diluted Earnings per Share from Continuing Operations

$

4.94(1) Represents a non-cash charge related to healthcare reform
impacting Medicare Part D reimbursements.  
Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369


'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
2. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
3. SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion
4. Hologic Announces Third Quarter Fiscal 2011 Operating Results
5. Medela Announces 2011 Breastfeeding Hall of Excellence Inductees to Nationally Recognize Exceptional Breastfeeding Advocates
6. Misonix Announces New Distribution Agreement for Chile
7. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference
8. Omnicell Announces Second Quarter 2011 Results
9. BioMarin Announces Second Quarter 2011 Financial Results
10. McNeil Consumer Healthcare Announces Plans for New Dosing Instructions for TYLENOL® Products
11. VeraLight Announces CE Mark Approval of the SCOUT DS® for Noninvasive Diabetes Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb.8, 2016 Cardiac ... Summary GlobalData,s Medical Devices sector report, ... Assessment, 2015 " provides an overview of Cardiac ... report provides comprehensive information on the pipeline products ... stages of development. The report reviews major players ...
(Date:2/8/2016)... Respiratory Devices - Medical Devices Pipeline ... sector report, " Respiratory Devices - Medical Devices ... Respiratory Devices currently in pipeline stage. The ... with comparative analysis of the products at various ... involved in the pipeline product development. It also ...
(Date:2/8/2016)... 2016 Aesthetic Devices - Medical Devices Pipeline ... report, "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" ... stage. This report is prepared using ... by GlobalData,s team of industry experts. *Note: Certain ... based on the availability and relevance of data in ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has published a ... a basic understanding of the techniques they use so they can more easily ... reduce waste and rework to create a leaner overall lab experience. , ...
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications collaborated ... Prevention,” an animated video designed to prevent the next widespread Ebola ... video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and ...
(Date:2/9/2016)... ... ... and Kevin Harrington, and the Product Managers of AsSeenOnTV.pro are pleased to announce the ... that has solved some of the basic problems golfers have faced since the dawn of ... a rain shower, might understand the struggle of placing the club down for a split ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
Breaking Medicine News(10 mins):